Investigation of Cisplatin-Related Kidney Toxicity

Completed

Conditions studied: Cancer

In brief

The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin. This study will also collect DNA for future analysis.

Key facts

Study ID

NCT00984035

Run by

University of Chicago

People needed

102

Starts

2009-09-22

Expected to finish

2018-03-01

Last updated by the study team

2018-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy.
• Aged 18 years and older.
• Ability to understand and willingness to sign a written consent document.
• Patients may be receiving cisplatin in combination with other chemotherapeutic agents.
• Patients may be receiving cisplatin in the context of another clinical trial.

You may not qualify if…

• Prior receipt of cisplatin.
• Patients on dialysis or other renal replacement therapy prior to starting cisplatin.
• Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible).
• Retrospective Analysis Group
• Inclusion Criteria:
• Patients that have previously received intravenous cisplatin as part of cancer chemotherapy.
• Aged 18 years and older.
• Ability to understand and willingness to sign a written consent document.
• Patients that received cisplatin in combination with other chemotherapeutic agents are eligible.
• Patients that received cisplatin in the context of a clinical trial are eligible.
• Exclusion Criteria:
• Unable or unwilling to submit to a one-time blood draw.

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.